Cipla, the Mumbai based pharmaceutical firm is about to launch the coronavirus drug Favipiravir. It has been developed by the CSIR and to make it cost effective the CSIR-IICT (Indian Institute of Chemical Technology) has utilized the locally available chemicals to produce the API (Active Pharmaceutical Ingredient) and gave its technology to Cipla. As the anti-viral drug Favipiravir, has shown promising outcomes in mild and moderate cases of Covid-19 during its clinical trials.
Updating about the news CSIR twitted;
Cost Effective Process Technology of Favipiravir Developed by CSIR Used by M/s Cipla Ltd., for Scale up & the Repurposed Drug Expected to be Launched Soon. @csiriict @Cipla_Global @shekhar_mande https://t.co/7WxVqUK4CI— CSIR (@CSIR_IND) July 23, 2020
They further stated that, “Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from COVID-19“.